The need to review the current instructions for use and adaptation to the over-the-counter status of the drug has been identified.
1. From the section "Indications for use" it is necessary to exclude the following indications: treatment of viral hepatitis A, B and C, cytomegalovirus infection; treatment in the complex therapy of infectious and allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis, etc.), urogenital and respiratory chlamydia, pulmonary tuberculosis.
2. In the section "Contraindications" add "Children's age to 18 years (for a dosage of 125 mg)".
3. In the "Method of administration and dose" section, remove the dosing regimen according to indications that do not meet the requirements of OTC (see paragraph 1).